Projects

1 - 10 of 31 results

Sorteren op
Search term:

Mechanical Circulatory Support in critically ill cardiogenic shock patients: a complex process of Thrombosis and Hemostasis. KU Leuven

Christophe Vandenbriele
Cardiology
The success of mechanical circulatory support (MCS) has greatly increased due to improved oxygenators, better design of the heart pumps and certainly due to better medical management. Nevertheless mortality of patients undergoing MCS remains high (50%) and complications are frequent. Paradoxically, the most common complications are both (life-threatening) bleeding (40-50%) ánd thrombosis as recently confirmed in a large US-trial covering ...

Pin'ning down Endothelial dysfunction and Thrombosis in Chronic thromboembolic pulmonary hypertension KU Leuven

Marion Delcroix
Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Universiteit Leiden

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of pulmonary embolism (PE), characterized by fibro-thrombotic material obliterating large pulmonary arteries. The incidence of CTEPH after PE is about 3%, with patients presenting at advanced stages with compromised haemodynamic profile and limited exercise capacity. Treatment is complex, involving surgery, angioplasty and drugs. There is an urgent need to i) ...

Thrombosis in COVID-19:dysregulation of the tromboinflammatory VWF/ADAMTS13 axis? KU Leuven

Simon De Meyer
Cardiovascular Sciences, Kulak Kortrijk Campus, Chemistry, Kulak Kortrijk Campus

Despite COVID-19 principally being a respiratory disease, there is an increasing amount of concern about the hypercoagulability and prothrombotic state of COVID-19 patients, especially in those who are critically ill. The infection initiates a potent inflammatory response that can stimulate thrombosis. Von Willebrand factor (VWF) is a large multimeric protein that is involved in both inflammatory and thrombotic processes. We hypothesize that ...

Treatment and prevention of thrombotic thrombocytopenic purpura in a unique animal model. KU Leuven

Karen Vanhoorelbeke
Chemistry, Kulak Kortrijk Campus
Thrombotic thrombocytopenic purpura (TTP) is a condition of the Blood characterized by systemic thromboses, hemolysis and thrombocytopenia. The disease is rather rare, but mortal. Current therapy has reduced mortality, but is pragmatic involving delivery of donor plasma products through a catheter. This method has the inherent risk of local inflammation, infection, and rejection. Alternative therapies are being developed, but preclinical data ...

Genome medicine for bleeding, thrombotic and platelet disorders KU Leuven

Kathleen Freson
Centre for Molecular and Vascular Biology
Platelets, the 2nd most abundant cell in the blood, play an essential role in cardiovascular disease. Inherited bleeding, thrombotic and platelet disorders (BTPD) are characterized by marked genetic heterogeneity. The list of genes involved in the regulation of platelet formation and function and bleeding or thrombosis has been growing rapidly to almost 100 genes since the introduction of high-throughput sequencing (HTS) approaches in research. ...

Study of the protective role of mitral valve regurgitation on the thrombotic risk in nonrheumatic atrial fibrillation: an experimental and human research model University of Antwerp

Marc Claeys
Cardiovascular diseases (CARDIOVASC)
Atrial fibrillation (AF) is highly prevalent and patients with AF have an increased thromboembolic risk compared to healthy individuals that can lead to stroke or systemic thromboembolism. Oral anticoagulants are used to prevent the occurrence of clinical thromboembolic events in AF patients with a high thrombotic risk (calculated by the CHA2DS2-VASc score). The use of oral anticoagulants, however, is accompanied by an increase in bleeding risk, ...

Study of the protective role of mitral valve regurgitation on the thrombotic risk in nonrheumatic atrial fibrillation: an experimental and human research model. University of Antwerp

Marc Claeys
Physiopharmacology (PHYSPHAR), Cardiovascular diseases (CARDIOVASC)
Atrial fibrillation (AF) is very prevalent and patients with AF have an increased thromboembolic risk compared to healthy individuals that can lead to stroke or systemic thromboembolism. Oral anticoagulants are being used to prevent the occurrence of clinical thromboembolic events in AF patients with a high thrombotic risk (calculated by the CHA2DS2-VASc score). The use of oral anticoagulants, however, is accompanied by an increase in bleeding ...

Innovative approaches to tackle autoimmune diseases: immune-mediated thrombotic thrombocytopenic purpura as a disease model KU Leuven

Karen Vanhoorelbeke
Chemistry, Kulak Kortrijk Campus
Long-term treatment of autoimmune disorders is still an unmet clinical need. In this project, we will develop innovative therapies to realize long-term treatment of autoimmune disorders. The autoimmune disorder immune-mediated TTP (iTTP) will serve as the disease model as the autoimmune response in iTTP is well known and autoantibodies are directed against only one antigen. In WP1, we will develop the chimeric antigen receptor ...

Towards improved thrombolysis in acute ischemic stroke KU Leuven

Simon De Meyer
Cardiovascular Sciences, Kulak Kortrijk Campus
Ischemic stroke is caused by a blood clot that is occluding part of the cerebral vasculature. This leads to focal impairment of the downstream blood flow and irreversible damage of the associated brain tissue. The mainstay of ischemic stroke therapy is timely recanalization of the occluded artery by targeting the occluding thrombus, either by pharmacological thrombolysis (using t-PA) or by mechanical thrombectomy. However, pharmacological ...

Validation study of the open ADAMTS13 conformation assay as a novel biomarker for correct diagnosis and predicting relapse in immune mediated thrombotic thrombocytopenic purpura KU Leuven

Karen Vanhoorelbeke
Chemistry, Kulak Kortrijk Campus
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare autoimmune disorder caused by neutralizing antibodies against the blood protease ADAMTS13. In the current guidelines, the diagnosis of iTTP is established by an ADAMTS13 activity below 10% and presence of anti-ADAMTS13 autoantibodies. While both two biomarkers have proven very useful in TTP diagnosis, there are still seronegative gaps in TTP diagnosis. We recently discovered ...